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Abstract 
Context: Glucocorticoid-induced myopathy is a characteristic symptom of endogenous Cushing’s 
syndrome (CS). Its long-term outcome is largely unknown.
Objective: To evaluate long-term muscle function following the remission of endogenous CS.
Study Design: Observational longitudinal cohort study.
Setting: Tertiary care hospitals and a specialized outpatient clinic.
Patients: As part of the prospective multicenter German Cushing’s Registry, we assessed muscle 
strength in patients with overt endogenous CS. We studied the patients at the time of diagnosis (n = 88), 
after 6 months (n = 69), and thereafter annually, following surgical remission over a period of up to 
4 years (1 year: n = 55; 2 years: n = 34; 3 years: n = 29; 4 years: n = 22). Muscle function was evaluated by 
hand grip strength and by chair rising test.
Results: Grip strength was decreased to 83% of normal controls (100%) at the time of diagnosis. It 
further decreased to 71% after 6 months in remission (P ≤ 0.001) and showed no improvement during 
further follow-up compared with baseline. Chair rising test performance improved initially (8 seconds at 
baseline vs 7 seconds after 6 months, P = 0.004) but remained at this reduced level thereafter (7 seconds 
after 3 years vs 5 seconds in controls, P = 0.038). In multivariate analysis, we identified, as predictors 
for long-term muscle dysfunction, age, waist-to-hip ratio, and hemoglobin A1c at baseline. Furthermore, 
muscle strength during follow-up was strongly correlated with quality of life.
Conclusion: This study shows that CS-associated myopathy does not spontaneously resolve during 
remission. This calls for action to identify effective interventions to improve muscle dysfunction in this 
setting.
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Glucocorticoid-induced myopathy with self-reported 
muscle weakness is present in up to 60% of patients with 
florid Cushing’s syndrome (CS). It is reported to be more 
frequent in men than in women (1, 2). The development of 
proximal muscle wasting and weakness is also a typical side 
effect of systemic glucocorticoid treatment. Based on the 
common use of steroids for the treatment of several med-
ical conditions, exogenous glucocorticoids have become the 
most common reason for drug-induced myopathy (3).
Cushing’s syndrome-associated myopathy particularly 
affects the proximal part of the limbs (4). The clinical man-
agement of glucocorticoid-induced myopathy is difficult, 
as patients typically experience relevant muscular impair-
ment at the time of initial diagnosis. Quantitative muscle 
ultrasound is proposed to be a useful diagnostic tool for the 
detection of CS before the development of symptoms (5). 
A specific therapy is not available so far, and current treat-
ment recommendations consist of adequate protein intake 
and moderate physical exercise (6–9). Given that endogenous 
CS is a rare disease, so far, associated myopathy has been 
studied only in small patient cohorts. Several characteristic 
clinical features of CS, including cognitive impairments, fa-
tigue, and an increased cardiovascular risk, can persist even 
years after a successful cure (10, 11). We and others have 
suggested that CS-associated myopathy and muscle damage 
may continue in the early recovery phase after successful 
treatment (12–14), but its long-term prognosis and out-
come is unknown. In retrospective, cross-sectional studies, 
patients in long-term remission showed decreased muscle 
strength and a lower aerobic exercise capacity compared to 
controls (14, 15). Whether this finding is due to a long-term 
change of muscle fibers in terms of an irreversible myopathy 
or due to a persisting cardiorespiratory dysfunction remains 
controversial. To analyze the long-term outcome of muscle 




The study was performed as part of the German Cushing’s 
Registry, a multicenter longitudinal cohort study, which has 
enrolled a total of 317 patients in 6 centers since 2012. 
For the current prospective study, we selected 88 patients 
with endogenous CS and consecutive muscle function tests 
diagnosed between 2012 and 2018 at 3 sites of the German 
Cushing’s Registry (Ludwig Maximilians University 
Munich, n  =  66; University Hospital Würzburg, n  =  18; 
Endocrinology outpatient clinic in Charlottenburg, Berlin, 
n = 4). All patients had typical signs and symptoms of CS. 
The diagnosis and subtype differentiation of CS were done 
as reported earlier according to current guidelines and re-
commendations (14, 16). All 88 patients (49 with Cushing’s 
disease, 34 patients with cortisol-producing adrenal ad-
enoma, and 5 patients with ectopic CS) were followed-up 
prospectively. Patients with subclinical hypercortisolism, 
adrenocortical cancer, and adrenostatic or radiothera-
peutic therapy were excluded. All 88 patients underwent 
successful surgery, leading to sustained biochemical remis-
sion. In 9 cases with pituitary CS, a second surgery was 
necessary to achieve remission. Median time to remission 
from diagnosis was 2 months, and median time to remis-
sion from the first symptoms was 25 months. Due to pre-
existing rheumatic disorders or degenerative joint diseases 
(ie, coxarthrosis), 13 patients could not perform either grip 
strength or the chair rising test (CRT). Out of all 88 pa-
tients included with baseline muscle function examination, 
grip strength data was available from 85 patients and CRT 
data from 78 patients. Patients were re-examined clinic-
ally and biochemically in regular follow-up visits 6 and 
12 months after final surgery, and afterwards annually. Due 
to a shorter remission time of recently included patients, 
the number of patients decreases with time (6  months: 
n = 69; 1 year: n = 55; 2 years: n = 34; 3 years: n = 29; 
4 years: n = 22). The mean follow-up for all patients with 
CS was 2.2 years. Only patients with at least 1 follow-up 
visit in addition to baseline visit were included in the study. 
For the comparison of muscle function, we recruited a con-
trol group of rule-out CS patients who had no biochemical 
evidence of CS. The control group (n = 29) was matched 
according to body mass index (BMI), age, and gender of 
patients with CS who have been in remission for 3 years 
(n = 29; Supplement Table 1; all supplementary material 
and figures are located in a digital research materials re-
pository (17)). All patients and controls gave written, in-
formed consent. The protocol was approved by the ethics 
committee of the participating centers.
Muscle strength measurements
Hand grip strength was measured 3 times on both hands 
per visit in a sitting position. The measurements were 
performed in a standardized manner with the JAMAR 
hydraulic hand dynamometer (Patterson Medical, 
Nottinghamshire, UK). The mean grip strengths (kg) for 
the dominant and nondominant hand were calculated 
out of 3 repetitions. The hand with the better perform-
ance at baseline was defined as the dominant hand. To 
adjust for age and gender, grip strength was standard-
ized (normalized grip strength) to the manufacturer’s 
information on normative grip strength data (18, 19). 
Mean normalized grip strength was determined from the 
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according to age and gender. To determine muscle func-
tion of the lower limbs, CRT was performed, as previ-
ously described in other studies (14, 20). The test was 
conducted by rising up from a sitting position 5 times 
as fast as possible. The patients kept their arms crossed 
over their chest while performing the exercise. The time 
(seconds) needed for the procedure (with ending in a 
standing position) was recorded and compared.
Bioimpedance measurements and biometrics
By using a bioimpedance measuring device at 50 kHz with 
400  µA by Data Input (Poecking, Germany), body cell 
mass and body fat percentage was estimated according 
to the manufacturer’s information. Two pairs of current-
introducing and voltage-sensing electrodes were attached 
to the dorsum of a hand and a foot. All impedance meas-
urements were taken after fasting, the arms relaxed at the 
sides without touching the body. Bioimpedance and an-
thropometric measurements such as BMI and waist-to-hip 
ratio (WHR) were performed by the same skilled investi-
gator in a standardized manner.
Quality of life
To analyze quality of life in patients with CS, 2 inventories 
were used: the disease-specific questionnaire, Cushing’s 
quality of life (CushingQoL) (21), and the Short Form 36 
health survey (SF-36) (22). The SF-36 Physical Component 
Summary and SF-36 Mental Component Summary were 
gained by weighting and summing up the original scales of 
the SF-36 according to Ellert et al (23), and in relation to a 
German normative population (24).
Laboratory analysis
In all patients, blood samples were taken in a fasting state 
at time of diagnosis, 6 months after successful surgery and 
in line with the follow-up visits once a year. The analyses 
were performed in the central laboratories of the involved 
centers using standard methods.
Statistical evaluation
Statistical analysis was performed using SPSS (version 
25). Patient characteristics are shown as median and 
25th and 75th percentiles in brackets. For comparison be-
tween different time points, the Wilcoxon signed rank 
test was used. Differences between the groups were ana-
lyzed using the Mann-Whitney U test and Kruskal–Wallis 
test. Based on a difference of 23% in normalized grip 
strength and 2 seconds in CRT after 3 years, a power of 
0.8 and P-level of 0.05, the study required the participa-
tion of a minimum of 18 patients per group. Because of 
the decreasing number (<20) of patients with CS after 
5  years, we limited the observation period to 4  years. 
To identify independent variables influencing muscle 
strength, outcome correlations between muscle strength 
and clinical parameters were determined using the 
Spearman’s rank correlation coefficient. Multiple linear 
regression analysis was performed with the variables of 
age, WHR, and hemoglobin A1c (HbA1c). P-values of 
<0.05 were considered to indicate statistical significance.
Results
Patient characteristics
Table  1 shows the clinical and biochemical characteris-
tics of the included patients with CS. Due to pre-existing 
rheumatic diseases or chronic degenerative arthropathies, 
3 and 10 patients, respectively, could not participate in 
grip strength measurements or CRT. Six months after 
successful surgery, we observed the expected reduction in 
BMI (P ≤ 0.001), WHR (P ≤ 0.001 in females, P = 0.008 in 
males), and HbA1c (P ≤ 0.001; Table 1).
Grip strength temporarily worsens during steroid 
withdrawal and remains impaired in long-term 
follow-up
Mean age- and gender-corrected grip strength of the 
dominant and nondominant hand (mean normalized 
grip strength) decreased from 83% at diagnosis to 71% 
6 months after successful treatment (P ≤ 0.001 vs baseline, 
Fig. 1A and 1B). One year after surgery, mean normalized 
grip strength had slightly increased to 77% (P = 0.036 vs 
6 months) and remained stable at this reduced level without 
further improvement during follow-up until the end of 
the observation period at 4  years (P  =  0.030 at 4  years 
follow-up vs controls, Fig. 1A).
Chair rising test performance initially improves 
but remains impaired during long-term follow-up
Patients with CS in remission showed improved CRT per-
formance 6  months after successful surgery compared 
with baseline (median 8 seconds vs 7 seconds at 6 months 
follow-up, P = 0.004, Fig. 2A and 2B). No further improve-
ment was observed over the next 4 years. Compared with 







































































The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 12 e4493
Figure 1. A: Age- and gender-corrected grip strength (%) in patients with Cushing’s syndrome (CS) at baseline and after successful surgery. Box 
and whiskers (10th to 90th percentile). Baseline: n = 85; 6 months (mo): n = 69; 1 year (y): n = 55; 2 y: n = 34; 3 y: n = 29; 4 y: n = 22; control: n = 29. 
Comparisons over time were performed by a Wilcoxon signed rank test and comparisons with control by a Mann-Whitney U test. P < 0.05 was con-
sidered statistically significant; *P < 0.05 vs baseline, ** P < 0.05 vs 6-mo follow-up, # P < 0.05 vs control; the higher percentage indicates greater 
muscle strength. B: Relative changes to baseline in mean normalized grip strength (%) of all patients with CS in remission. Data are given as 
mean ± SEM.
Table 1. Baseline and 6-month follow-up characteristics of all patients with Cushing’s syndrome
Patient Characteristics Reference 
Interval
n Baseline 6-month Remission P-value Baseline vs 
6-month Remission
Sex, female/male – 88 69 (78%) /19 (22%) – –
Age, years – 88 49 [40; 59] – –
Diagnosis, pituitary/adrenal/ectopic – 88 49 (56%)/34 (38%)/5 
(6%)
– –
Time to remission from diagnosis, months – 88 2 [1; 5] – –
Time to remission from first symptoms, 
months
– 88 25 [12; 74] – –
Pre-existing diabetes mellitus, yes/no – 88 22 (25%)/66 (75%) – –
Bone density, T-score – 46 -1.6 [-2.0; -0.9] – –
BMI, kg/m2 – 88 29 [25; 33] 27 [24; 31] ≤0.001
Waist-to-hip ratio, female <0.85 61 0.94 [0.87; 1.02] 0.91 [0.82; 0.96] ≤0.001
Waist-to-hip ratio, male <0.90 19 1.04 [1.00; 1.12] 0.93 [0.89; 0.98] 0.008
HbA1c, % – 86 5.9 [5.4; 6.4] 5.5 [5.2; 6.1] ≤0.001
HOMA-Index – 72 3.3 [2.0; 5.0] 2.4 [1.1; 4.7] 0.341
UFC, µg/24h ≤83.0 86 366 [196; 708] 35 [7; 61] ≤0.001
LNSC, ng/mL ≤1.5 85 7.2 [3.5; 11.9] 0.9 [0.4; 1.7] ≤0.001
DST, 1 mg ≤2.0 86 14.2 [7.1; 23.5] 1.1 [1.0; 1.7] ≤0.001
ACTH in pituitary CS, pg/mL 4–50 49 54 [30; 91] 11 [5; 19] ≤0.001
ACTH in adrenal CS, pg/mL 4–50 34 4 [2; 5] 9 [5; 20] ≤0.001
ACTH in ectopic CS, pg/mL 4–50 5 103 [66; 253] 11 [4; 23] 0.043
Data are given as median and 25th and 75th percentile in brackets. Comparisons were performed by a Wilcoxon signed rank test. Bold P-values indicate statistical 
significance.
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; CS, Cushing’s syndrome; DST, dexamethasone suppression test; HbA1c, hemoglobin 
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CS at 3 years follow-up vs 5 seconds in controls, P = 0.038, 
Fig. 2A).
Factors influencing long-term outcome
We identified age, WHR, and HbA1c at the time of diag-
nosis as associated with the long-term muscle function 
outcome at 3 years in univariate and multivariate analysis 
(Tables 2 and 3 and Supplement Fig. 1; all supplementary 
material and figures are located in a digital research ma-
terials repository (17)). Consistent with these findings, a 
subgroup analysis of patients with pre-existing diabetes 
mellitus revealed a poorer CRT performance at 3  years 
(P = 0.009 vs patients without pre-existing diabetes mel-
litus), whereas Cushing subtype or duration of CS mani-
festation prior to surgery had no significant influence 
(Table 2). In a subgroup analysis of 29 patients followed 
for more than 3  years, patients with long-term gluco-
corticoid replacement therapy (n  =  16) showed similar 
muscle strength compared with patients without gluco-
corticoid replacement (n = 13). Urinary free cortisol, late 
night salivary cortisol, and 1 mg dexamethasone suppres-
sion test at diagnosis did not correlate with muscle strength 
outcomes. Moreover, quality of life, BMI, estimated muscle 
mass, and body fat percentage at baseline were not associ-
ated with muscle strength outcome (Supplement Table 2; 
all supplementary material and figures are located in a 
digital research materials repository (17)).
Figure 2. A: Chair rising test performance (seconds) of patients with Cushing’s syndrome (CS) at baseline and after successful surgery. Box and whis-
kers (10th to 90th percentile). Baseline: n = 78; 6 months (mo): n = 64; 1 year (y): n = 50; 2 y: n = 29; 3 y: n = 28; 4 y: n = 21; control: n = 29. Comparisons 
over time were performed by a Wilcoxon signed rank test and comparisons with control by a Mann-Whitney U test. P < 0.05 was considered statistic-
ally significant; * P < 0.05 vs baseline, # P < 0.05 vs control. Shorter time (seconds) indicates greater muscle strength. B: Relative changes to baseline 
in chair rising test performance (%) of all patients with CS in remission. Data are given as mean ± SEM.
Table 2. Correlation analysis of predictor variables at 
baseline and long-term muscle function after 3 years in 





n P-value Spearman’s 
Coefficient
Age GS 29 0.934 0.019
CRT 28 ≤0.001 0.598
WHR GS 29 0.014 -0.514
CRT 28 0.010 0.478
HbA1c GS 29 0.495 -0.153
CRT 28 0.009 0.485




GS 29 0.474 0.138





GS 20 vs 8 vs 1 0.794 –





GS 10 vs 19 0.910 –
CRT 9 vs 19 0.009 –
Decreasing values of GS corresponds to increased upper limb myopathy; 
increasing values of CRT corresponds to increasing lower limb myop-
athy. Correlations were performed by a Spearman’s correlation analysis. 
Comparisons were performed by a Mann-Whitney U test, and for more than 2 
groups by a Kruskal–Wallis test. Bold P-values indicates statistical significance.
Abbreviations: CRT, chair rising test; GS, grip strength; HbA1c, hemoglobin 
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Changes of body composition
Anthropometric measurements showed the expected fast de-
crease in BMI and WHR after successful surgery (Table 1). 
By performing bioimpedance measurements, body fat per-
centage and body cell mass (as surrogates for muscle mass) 
could be estimated. Concerning estimated muscle mass, no 
relevant differences were observed between baseline and 
follow-up assessments (Supplement Fig. 2; all supplemen-
tary material and figures are located in a digital research 
materials repository (17)). At baseline, estimated muscle 
mass of 25 kg correlated with bone density (median T-score 
-1.6, P = 0.017). Body fat percentage decreased from 35% 
at baseline to 33% at 6 months (P = 0.045) and 29% at 
1-year follow-up (P  = 0.003, Supplement Fig. 2; all sup-
plementary material and figures are located in a digital re-
search materials repository (17)).
Muscle function is associated with quality of life
Quality of life improved over time according to both the 
CushingQoL and SF-36 questionnaires (Supplement Table 3; 
all supplementary material and figures are located in a 
digital research materials repository (17)). Spearman’s 
correlation analysis showed a strong correlation between 
muscle function and quality of life during follow-up 
(Table 4). These data suggest that impaired quality of life 
not only depends on the severity of muscle dysfunction 
during hypercortisolism but also on the myopathy outcome 
in patients with CS in remission.
Discussion
This is the first prospective longitudinal study investigating 
the long-term outcome of CS-associated myopathy. The 
main finding of our study is that muscle strength remains 
impaired even after years in remission, and independent 
of glucocorticoid replacement status. Another interesting 
finding is that at 6  months follow-up, grip strength and 
CRT performance show opposite effects; whereas grip 
strength has worsened, CRT performance has improved. 
Because of a correlation between CRT performance and 
BMI at baseline (P = 0.007), it is likely that an improve-
ment in CRT after achieving remission is due to the consid-
erable reduction in BMI. However, grip strength remained 
impaired and showed no improvement during follow-up, 
Table 3. Results of multivariate linear regression model of 
muscle strength measurements 3 years after treatment and 







β P-value R2 P-value
CRT  
performance
   0.288 0.011
Age 0.469 0.031   
WHR 0.093 0.655   




   0.308 0.083
Age 0.173 0.479   
WHR -0.604 0.016   
HbA1c 0.067 0.801   
Bold P-values indicate statistical significance.
Abbreviations: β, beta; CRT, chair rising test; HbA1c, hemoglobin A1c; WHR, 
waist-to-hip ratio.
Table 4. Correlation between muscle function outcome and quality of life in patients with Cushing’s syndrome in remission
Time Points Muscle Function QoL Questionnaire n P-value Spearman’s Coefficient
Baseline CRT CushingQoL 53 0.030 -0.298
SF-36 PCS 57 0.002 -0.410
6 months CRT CushingQoL 39 0.042 -0.327
SF-36 PCS 42 0.007 -0.413
1 y CRT SF-36 PCS 30 ≤0.001 -0.626
2 y CRT CushingQoL 21 ≤0.001 -0.714
SF-36 PCS 22 ≤0.001 -0.668
SF-36 MCS 22 0.013 -0.522
3 y Grip strength CushingQoL 17 0.050 0.480
4 y Grip strength CushingQoL 10 0.029 0.685
CRT CushingQoL 10 0.010 -0.766
SF-36 PCS 11 ≤0.001 -0.834
SF-36 MCS 11 0.010 -0.737
Baseline and follow-up assessments before and after successful treatment. Worse muscle function in CRT corresponds to higher readings, while worse muscle func-
tion in grip strength corresponds to lower readings. Correlations were performed by Spearman’s correlation analysis. Bold P-values indicate statistical significance.
Abbreviations: CRT, chair rising test; CushingQoL, Cushing’s quality of life; QoL, quality of life; SF-36 MCS = Short Form 36 Mental Component Summary; SF-36 
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while the temporary worsening of grip strength during the 
steroid withdrawal phase seems to be reversible. Despite 
biochemical remission, myopathy can thus be regarded as 
another persistent clinical symptom, as it is known for cog-
nitive function, mental fatigue, and cardiovascular risk (10, 
11, 25). Why patients with CS in remission showed a tem-
porary worsening in grip strength 6 months after surgery 
remains unclear in term of pathophysiology. That muscle 
function and thus myopathy is affected by glucocorticoid 
withdrawal due to a relative glucocorticoid resistance or 
inflammatory processes is quite conceivable (26, 27). Also, 
high-dose glucocorticoid replacement for the prevention 
of a steroid withdrawal syndrome directly after surgery 
could account for the transient aggravation. Grip strength 
measurements performed by the JAMAR hydraulic hand 
dynamometer depends on muscle function but also re-
quires an intact function of joints and connective tissue. 
It is possible that muscle and joint pain, which can as well 
be provoked by glucocorticoid withdrawal, affect strength 
measurements.
As predictors for myopathy outcome and muscle func-
tion in remission of CS, we identified age, WHR, and 
HbA1c. Age correlated inversely with relative changes of 
grip strength and CRT in relation to baseline (Supplement 
Fig. 1; all supplementary material and figures are located 
in a digital research materials repository (17)). Moreover, a 
high WHR and HbA1c at baseline were associated with a 
poorer outcome in muscle function (Tables 2 and 3), while 
BMI and body fat percentage estimated with bioimpedance 
measurements were not. These results suggest that particu-
larly an unfavorable fat distribution with elevated WHR 
and diabetic metabolic state contributes to adverse out-
come of myopathy. These findings are concordant with our 
previous analysis of patients with florid CS and matched 
obese controls, where we found that patients suffering 
from both hypercortisolism and impaired fasting glucose 
had the strongest impairment in grip strength and CRT 
performance, implicating impaired glucose metabolism 
as an important driver in the pathomechanism of myop-
athy. According to our data analysis we assume that im-
paired glucose metabolism affects both muscle function 
during hypercortisolism and the long-term outcome of 
CS-associated myopathy. The link between impaired muscle 
function and diabetes has already been described, but the 
underlying pathomechanisms remain largely unclear (28). 
Furthermore, other factors such as growth hormone and 
sex hormone suppression are proposed to play a crucial 
role in influencing CS-associated myopathy in the long run 
(29, 30).
Whether the necessity of a long-term glucocorticoid re-
placement influences muscle strength or myopathy outcome 
remains controversial. Geer et  al found an inverse correl-
ation between duration of glucocorticoid replacement and 
skeletal muscle mass in patients with CS in remission, sug-
gesting continued muscle loss resulting from glucocorticoid 
replacement therapy (13). In our subgroup analysis of 29 
patients followed for more than 3  years in remission, we 
could not observe any differences in muscle function or es-
timated muscle mass by bioimpedance measurements be-
tween patients with or without glucocorticoid replacement 
3 years after surgical cure. Consistent with previous findings 
on the body composition of patients with CS in remission 
(12), estimated body fat percentage decreased, whereas es-
timated muscle mass remained at a constant level. These re-
sults indicate that weight loss and reduction of BMI after 
successful treatment is most likely due to a loss of body fat 
than due to continuing muscle loss after hypercortisolism. 
However, clinically manifest—even though subclinical—
hypercortisolism was associated with muscle waste and 
the severity of hypercortisolism was correlated with lower 
muscle mass (31, 32), the remission of CS exhibited no rele-
vant gain in muscle function or muscle mass (12, 13). The 
severity of cortisol excess in patients with adrenal CS was 
also reported to be related to visceral fat area, visceral-to-
subcutaneous fat ratio and skeletal muscle radiodensity 
1  year after adrenalectomy (33). In a recently published 
cross-sectional study with 17 patients, Roerink et  al re-
ported a reduced aerobic exercise capacity after years in re-
mission. Due to nonsignificant differences in muscle fiber 
cross-sectional area and capillarization, impaired aerobic 
capacity was explained by a persisting cardiac dysfunction, 
as seen in patients with florid CS (15). In terms of pathology, 
muscle biopsy in glucocorticoid-induced myopathy demon-
strated severe histochemical type-2 muscle fiber atrophy 
(34). Whether these alterations during hypercortisolism are 
reversible and whether intermuscular fat infiltration plays a 
critical role in its pathophysiology remains largely unknown 
(35). Likewise, if muscle atrophy leads to an abnormal glu-
cose metabolism or if a diabetic metabolic state promotes 
atrophy and/or fat infiltration is uncertain. We have recently 
shown that hand grip strength seems to be more susceptible 
to hypercortisolism in a glucocorticoid receptor A3669G 
wild type than in A3669G minor allele carriers, explaining 
the partially interindividual differences of glucocorticoid-
induced myopathy in patients with endogenous CS (36). 
Given the fact that corticosteroid-induced myopathy also 
affects 60% of patients receiving corticosteroid treatment 
(3), and muscle function showed a strong correlation with 
quality of life, especially in the long-term period, there is 
great importance to clarify pathophysiologic basics and 








































































The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 12 e4497
Strengths and limitations of the study
This is a prospective study with a reasonable number of 
patients having adequate statistically power. A limitation 
of the study is the decreasing number of patients with time 
in remission caused by the continuing longitudinal inclu-
sion of patients with florid CS between 2012 and 2018. 
Given that the statistical power of this study was calcu-
lated based on grip strength and CRT changes, it cannot 
be ruled out that the statistical power for other results 
and clinical parameters is insufficient. Some results might 
therefore change after all 88 patients have completed the 
4-year follow-up. Moreover, a further limitation could be 
a selection or observer bias, as the study was performed 
in 3 sites of the German Cushing’s Registry.
Conclusion
Muscle function of patients with CS in remission remained 
impaired in the long term. Influencing factors for myop-
athy outcome are age, WHR, and HbA1c, suggesting that 
a consistent and strict treatment of diabetic metabolic state 
during hypercortisolism is mandatory. Further studies are 
necessary to understand pathophysiology and to develop 
effective treatment options.
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